GGrantIndex
← Search

Imaging Research

$118,456P30FY2025CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

IMAGING RESEARCH SHARED RESOURCE PROJECT SUMMARY / ABSTRACT The mission of the Imaging Research Shared Resource (Imaging SR) has been to provide all regional cancer investigators with comprehensive preclinical and clinical imaging capabilities and services to deliver in vivo and in situ imaging assessments of cancer. Established in 2005, the Imaging SR has now grown to become a multi- institutional SR with two sites at Case Western Reserve (CWRU)/University Hospitals (UH) and Cleveland Clinic (CC) integrating comprehensive, state-of-the-art imaging capabilities for both animal models of cancer (CWRU/UH and CC sites), as well as pediatric and adult patients (CWRU/UH site). The Imaging SR is supported by a well-established operational and administrative infrastructure including centralized imaging facilities at each site led by Flask, Chen and Androjna (Co-Directors) and supported by 9 highly-skilled Imaging SR staff with over 100 years of combined imaging expertise. The aims of the Imaging SR are to provide both imaging services and training on state-of-the-art imaging systems to all regional cancer investigators including: 1) high-volume preclinical bioluminescence and fluorescence imaging services; 2) custom-designed radionuclides for preclinical PET imaging capabilities to assess tumor progression, therapy, and metabolism; 3) novel in situ cryo- fluorescence imaging to direct cell/gene therapies; 4) MRI and MR Fingerprinting assessments for both mouse cancer models and cancer patients. Importantly, imaging services at both sites are available to all regional investigators through established, compliant inter-institutional agreements and operational processes. The capabilities and services provided by the Imaging SR have significantly expanded during the current funding cycle through investments by regional institutions, the NIH, and industrial collaborators including: 1) two new research-dedicated Siemens Vida 3T human MRI scanners (CWRU/UH site, ~$5M investment by CWRU/UH and Siemens); 2) a new Cubresa PET insert for the first small animal PET-MRI in the region (CWRU/UH site, ~$400K from NIH S10 award); 3) an upgraded 9.4T small animal MRI scanner supporting MR Fingerprinting development (CWRU/UH site, ~$1.1M investment by CWRU); 4) a new Mediso nanoscan PET/CT (CC site, ~$900K from NIH S10 award); and 5) a new Vevo F2 rodent ultrasound to support novel nanobubble development (CWRU/UH site, ~$400K investment by CWRU). The custom radiochemistry synthesis capabilities provided by the CWRU/UH site are also available to both sites to support novel preclinical PET imaging studies.

View original record on NIH RePORTER →